Chronic Lymphocytic Leukemia | Specialty

BTK Combination Strategies for B-Cell Malignancies

March 4th 2019

BTK Inhibitors in Chronic Lymphocytic Leukemia

March 4th 2019

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

March 4th 2019

First-Generation BTK Inhibition in Mantle Cell Lymphoma

March 4th 2019

BTK Inhibitors in Waldenstrom Macroglobulinemia

March 4th 2019

Resistance to BTK Inhibitors in B-Cell Malignancies

March 4th 2019

BTK Inhibitors Explored in B-Cell Malignancies

March 4th 2019

Targeting BTK in B-Cell Malignancies

March 4th 2019

Genomic Profiling in Chronic Lymphocytic Leukemia

March 4th 2019

Diagnosing Waldenstrom Macroglobulinemia

March 4th 2019

Newer Agents Extend Survival and Reduce Toxicity in CLL

March 4th 2019

New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving.

Chemotherapy Poised to Have Minor Role in Future CLL Treatment

March 3rd 2019

The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia.

CLL Research Explores Feasibility of Time-Limited Treatment

February 22nd 2019

Nicole Lamanna, MD, highlights the latest MURANO data in CLL, delving into the need for more studies to test the feasibility of time-limited treatment in this patient population.

Ibrutinib Plus CAR T-Cell Therapy Boosts Response in CLL

February 22nd 2019

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

Novel CLL Regimens Show Promising Efficacy

February 20th 2019

Suman Kambhampati, MD, reflects on the emergence of data in chronic lymphocytic leukemia from the 2018 ASH Annual Meeting.

Ibrutinib/JCAR014 Combo Shows Potential in Relapsed/Refractory CLL

February 13th 2019

Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.

Dr. Kambhampati Discusses Data from the 2018 ASH Annual Meeting in CLL

February 13th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses data from the 2018 ASH Annual Meeting in chronic lymphocytic leukemia (CLL).

Dr. Arora on the Use of Venetoclax in CLL

February 8th 2019

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kahl on Frontline Therapy Selection in CLL

February 7th 2019

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).

Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL

February 6th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.